In this Healio Video Perspective, SriniVas R. Sadda, MD, discusses his paper on Nanoscope’s MCO-010 optogenetic therapy in advanced retinitis pigmentosa, which was presented at the Euretina congress in Amsterdam.
Sadda said he is “very excited” about the prospects of optogenetic therapy. Retinitis pigmentosa is the most common inherited retinal disease and is challenging because a number of mutations can cause the disease. This is why having a gene-agnostic type of treatment is going to be important, he said.
In the RESTORE phase 2b clinical trial, a substantial number of